Skip to content
Menu

Immunovant, Inc. IMVT

Full chart Compare
Set alert

Price alert · IMVT

All alert types
32.26 USD -0.26 (-0.80%)

As ofNov 20, 2026, 10:54 AM EST

32.02 Day range 32.77
21.86 52-week range 45.42
YTD
+26.91%
1 year
+41.55%

 

No chart data for this range yet.
Market cap
6.67B
EPS (ttm)
-2.56
Shares out
206.95M
Forward P/E
-11.53
YTD return
+26.91%
1-year return
+41.55%
50-day average
32.28
200-day average
32.46
Enterprise value
6.14B
Price / book
10.24
Volume
105.67K
Avg volume
1.42M
Open
32.07
Previous close
32.52
Day's range
32.02 – 32.77
52-week range
21.86 – 45.42
Beta
0.94
Analysts
Buy
Price target
48.63 (+50.7%)
Earnings date
Feb 5, 2027

Key statistics

Free cash flow
-230.54M
Total cash
722.27M
Return on equity
-86.51%
Short % of float
19.91%

Fundamental scorecard

6 of 25 checks passed on IMVT’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IMVT Revenue — quarterly 0
IMVT Net income — quarterly -97.25M
IMVT EPS — quarterly -0.47

Earnings

IMVT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 5, 2027Dec 30, 2026-0.64———
Nov 9, 2026Sep 30, 2026-0.73701-0.47+0.27+36.23%
Aug 6, 2026Jun 30, 2026-0.6289-0.75-0.12-19.26%
May 20, 2026Mar 31, 2026-0.59202-0.73-0.14-23.31%
Feb 6, 2026Dec 31, 2025-0.72-0.61+0.11+15.28%
Nov 10, 2025Sep 30, 2025-0.72-0.73-0.01-1.39%

Upgrades / downgrades

IMVT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026Truist SecuritiesmainHoldHold
Nov 10, 2026Wells FargomainOverweightOverweight
Aug 4, 2026JP MorganmainOverweightOverweight
Jun 30, 2026CitigroupmainBuyBuy
May 26, 2026GuggenheimmainBuyBuy
May 22, 2026Truist SecuritiesmainHoldHold

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on IMVT — it syncs with the Stock Master app.

Insider holders

IMVT insider holders
InsiderRelationLatest transactionDateShares held
BARNETT EVA RENEEChief Financial OfficerSaleApr 15, 2025396,774
GEFFNER MICHAELOfficerSaleOct 21, 2025217,958
GIRÃO TIAGO MChief Financial OfficerSaleJul 22, 2026240,798
GLORIA MELANIEChief Operating OfficerSaleAug 19, 2026219,301
LEVINE MARK SOfficerSaleNov 19, 2024319,228
MACIAS WILLIAM LOfficerSaleFeb 18, 2025357,353

Institution ownership

IMVT institution ownership
Holder% heldSharesValueReported
FMR, LLC7.59%15,704,154510.70MSep 29, 2026
Deep Track Capital, Lp4.43%9,160,801297.91MSep 29, 2026
Blackrock Inc.3.59%7,425,771241.49MSep 29, 2026
Farallon Capital Management LLC3.13%6,471,000210.44MSep 29, 2026
Morgan Stanley2.75%5,684,840184.87MSep 29, 2026
Two Seas Capital Lp2.23%4,612,692150.00MSep 29, 2026

Fund ownership

IMVT fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.46%5,092,337165.60MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.26%2,600,08684.55MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.09%2,251,14873.21MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.02%2,107,16368.52MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund0.91%1,881,79861.20MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.68%1,408,87245.82MSep 29, 2026